HVEM/TNFRSF14 Antibody (HMHV-1B18) - Chimeric - Azide and BSA Free

This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques.

This antibody has been used in FACS to demonstrate that lymphatic endothelial cells mediate deletion only via programmed cell death-1 (PD-1) ligand 1 (Tewalt et al 2012) and in Western Blot to study the role of LIGHT in the pathogenesis of hepatitis (Anand et al 2006). This antibody has been also been used in vivo experiments to study the mechanisms by which TNFSF14 functions to promote airway remodelling in asthma (Sibilano et al 2016), to confirm that costimulatory role through HVEM is not necessary for LIGHT-mediated liver inflammation (Anand et at 2006), and to investigate the role that herpesvirus entry mediator plays in the development of experimental conjunctivitis (Ishida et al, 2012). Treatment with this antibody has been observed to diminish plasma levels of antigen-specific IgG1 and IgE antibodies in mouse asthma models (Sibilano et al 2016), to interfere with the LIGHT-HVEM interaction but not interaction between B and T lymphocyte attenuator (BTLA) and HVEM in mouse hepatitis models (Anand et at 2006), and NOT to affect the development of experimental conjunctivitis in either the induction or the effector phase (Ishida et al, 2012).